06.12.2020 • News

US Judge Rejects Bayer’s PCB Settlement Plan

In yet another legal repercussion of Bayer’s 2018 acquisition of Monsanto, a US federal judge has rejected the German group’s proposed $648 million settlement of class-action litigation over historic contamination from polychlorinated biphenyls (PCBs).

The proposal was part of a $12 billion package announced in June this year, most of which covered litigation involving the US chemical group’s Roundup herbicide. In rejecting the PCB settlement, Fernando Olguin, district judge in Los Angeles, California, said it appeared “overly broad.”

Not only would the terms protect Bayer from future claims, Olguin said, they would also require the settling plaintiffs to indemnify the group against such claims. This, he noted, would affect most of the 2,528 class members. These included cities such as San Diego, California, Baltimore, Maryland, and Portland, Oregon, which stood to receive “very modest” payments of just $15,000 to $30,000. 

Olguin has given Bayer until the end of 2020 to adjust its proposal, a deadline the group has said it will meet.

Once widely used in applications ranging from equipment insulation to floor finish and paints and coatings, PCBs were banned by the US federal government in 1979 on suspicion that they could cause cancer and other health problems. Monsanto produced the chemicals from 1935 to 1977.

Author: Dede Williams, Freelance Journalist

A US federal judge has rejected Bayer’s proposed $648 million settlement of...
A US federal judge has rejected Bayer’s proposed $648 million settlement of class-action litigation over historic contamination from polychlorinated biphenyls. The judge has given Bayer until end 2020 to adjust its proposal, part of a $12 billion package announced in June. (c) Bayer

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.